Dermata Therapeutics, Inc. (DRMA): Nasdaq/NYSE listing notice — Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing

Dermata Therapeutics, Inc.

Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.
Received notice of non-compliance with $1.00 minimum bid price; securities subject to delisting.
Reverse stock split within past year triggers accelerated delisting; suspension possible May 23, 2025.
Company plans to request hearing by May 21, 2025 to stay suspension pending panel decision.
No assurance compliance plan will be accepted; delisting risk remains if plan fails.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Dermata Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

May 14, 2025, the Company received a letter from the Staff indicating that as of May 14, 2025, the Company has regained compliance with the Stockholder’s Equity Requirement and the matter is now closed. Minimum Bid Price On May 14, 2025, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 14, 2025, the Company received a letter from the Staff indicating that as of May 14, 2025, the Company has regained compliance with the Stockholder’s Equity Requirement and the matter is now closed. Minimum Bid Price On May 14, 2025, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation

View on SEC.gov

Browse all listing & compliance notices →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-011286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.